source
- Kyorin signs $140M deal for Japan rights to Edesa's ARDS antibodyKyorin Pharmaceutical will pay $12 million up front and up to $134 million in milestones, plus royalties, for exclusive Japan rights to Edesa Biotech’s anti‑TLR4 antibody, paridiprubart, intended f…
- Trump administration issues new guidelines to curb AI-driven bioweapon threatsThe White House announced a set of guidelines aimed at preventing the misuse of artificial intelligence in creating biological weapons. Officials said the rapid advances in AI-driven drug discovery…